V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Amgen Executive Compensation (FY25)

AMGN · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Robert Bradway
Latest say-on-pay support
=
May 19, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Amgen

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): May 20, 2026
13 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Amgen brief$1,500Get the executive brief
Velarion Member, one year
334 figures on this page: 325 cited to the filing that reported them, 9 calculated from figures it prints. See the citations

More on Amgen

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Robert Bradway: $24,428,495 → $24,693,120 (1.1% higher)
Say-on-pay support: 94.2% → 96.7% (2.5 points higher)
CEO pay ratio: 153:1 → 160:1 (4.6% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Amgen's chief executive and what were they paid?
Total compensation for Robert Bradway, Chief Executive Officer and President, came to $24,693,120 in fiscal 2025. Bradway's total moved 1.1% higher from the $24,428,495 reported for fiscal 2024.
What was Amgen's say-on-pay result?
The say-on-pay proposal drew 96.7% of votes cast including abstentions in favor at the meeting held May 19, 2026 for fiscal 2025.
Which companies are in Amgen's peer group?
The disclosed peer group includes AbbVie Inc., AstraZeneca plc, Biogen Inc., Bristol-Myers Squibb Company and Eli Lilly and Company, among others.
What is Amgen's chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 160:1, against median employee compensation of $154,123.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert A. Bradway
Chief Executive Officer and President
◇—◇◇◇—◇◇
Murdo Gordon
Executive Vice President, Global Commercial Operations
◇—◇◇◇—◇◇
David M. Reese
Executive Vice President and Chief Technology Officer
◇—◇◇◇—◇◇
Peter H. Griffith
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert A. Bradway
Chief Executive Officer and President
◇—◇◇◇—◇◇
Murdo Gordon
Executive Vice President, Global Commercial Operations
◇—◇◇◇—◇◇
David M. Reese
Executive Vice President and Chief Technology Officer
◇—◇◇◇—◇◇
Peter H. Griffith
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert A. Bradway
Chief Executive Officer and President
◇—◇◇◇—◇◇
James E. Bradner
Executive Vice President, Research and Development
◇◇◇◇◇—◇◇
Murdo Gordon
Executive Vice President, Global Commercial Operations
◇—◇◇◇—◇◇
David M. Reese
Executive Vice President and Chief Technology Officer
◇—◇◇◇—◇◇
Peter H. Griffith
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert Bradway
Chief Executive Officer and President
◇—◇◇◇—◇◇
James Bradner
Executive Vice President, Research and Development
◇◇◇◇◇—◇◇
Peter Griffith
Executive Vice President and Chief Financial Officer
◇—◇◇◇—◇◇
Murdo Gordon
Executive Vice President, Global Commercial Operations
◇—◇◇◇—◇◇
David Reese
Executive Vice President and Chief Technology Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
David ReesePSU◇—◇—◇—◇
David ReeseOPTION◇——◇—◇◇
David ReeseRSU◇——◇——◇
James BradnerRSU◇——◇——◇
James BradnerPSU◇—◇—◇—◇
James BradnerOPTION◇——◇—◇◇
Murdo GordonPSU◇—◇—◇—◇
Murdo GordonRSU◇——◇——◇
Murdo GordonOPTION◇——◇—◇◇
Peter GriffithOPTION◇——◇—◇◇
Peter GriffithPSU◇—◇—◇—◇
Peter GriffithRSU◇——◇——◇
Robert BradwayPSU◇—◇—◇—◇
Robert BradwayRSU◇——◇——◇
Robert BradwayOPTION◇——◇—◇◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Robert BradwayOption◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
PSU◇◇——
Peter GriffithOption◇—◇—
RSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
Murdo GordonOption◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
PSU◇◇——
RSU◇◇——
RSU◇◇——
James BradnerRSU◇◇——
Option◇—◇—
David ReesePSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
David Reese
Chief Technology Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-solicit period◇
James Bradner
Executive Vice President · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance cash amount◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-solicit period◇
Murdo Gordon
Executive Vice President, Global Commercial Operations · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Non-solicit period◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Robert A. Eckert
Lead independent director
◇◇———◇◇
Ellen J. Kullman
◇◇———◇◇
Greg C. Garland
◇◇———◇◇
Charles M. Holley Jr
—◇———◇◇
S. Omar Ishrak
—◇———◇◇
Tyler Jacks
◇◇———◇◇
Brian J. Druker
◇◇———◇◇
Mary E. Klotman
◇◇———◇◇
Amy E. Miles
◇◇———◇◇
Wanda M. Austin
◇◇———◇◇
Michael V. Drake
—◇———◇◇
Robert A. Bradway served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Lead independent director premium◇
Audit committee chair◇
Equity is delivered as restricted stock units.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • AbbVie Inc. ABBV
  • AstraZeneca plc AZN
  • Biogen Inc. BIIB
  • Bristol-Myers Squibb Company BMY
  • Eli Lilly and Company LLY
  • Gilead Sciences, Inc. GILD
  • GlaxoSmithKline plc GSK
  • Johnson & Johnson JNJ
  • Merck & Co., Inc. MRK
  • Novartis AG NVS
  • Pfizer Inc. PFE
  • Regeneron Pharmaceuticals, Inc. REGN
  • Roche Holding AG symbol not shown
  • Sanofi S.A. SNY
  • Vertex Pharmaceuticals Incorporated VRTX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025May 19, 2026=◇◇◇
2024May 23, 2025=◇◇◇
2023May 31, 2024=◇◇◇
2022May 19, 2023=◇◇◇
2021May 17, 2022=◇◇◇
2020May 18, 2021=◇◇◇
2019May 19, 2020=◇◇◇
2018May 21, 2019=◇◇◇
2017May 22, 2018=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Robert Bradway (Chief Executive Officer and President), FY2025 total compensation $24,693,120 (base salary $1,925,409) [exec_comp, SEC accession 0001193125-26-145588, filed 2026-04-07]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when Amgen files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Amgen disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Amgen sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Amgen's disclosed peer group is defensible, who names Amgen back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
334 figures on this page: 325 cited to the filing that reported them, 9 calculated from figures it prints.
325 cited to the filing
9 calculated from the filing

Documents cited

  1. 0001193125-26-232786
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001193125-26-145588
    Compensation Discussion and Analysis · Director Compensation Table · Director Compensation · Grants of Plan-Based Awards · and 3 more sections
  3. 0000950170-25-077233
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0000950170-25-052315
    Summary Compensation Table
  5. 0001193125-24-153221
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001193125-24-099062
    Summary Compensation Table
  7. 0001193125-23-150659
    Item 5.07 Submission of Matters to a Vote of Security Holders
  8. 0001193125-23-093947
    Summary Compensation Table
  9. 0001193125-22-154061
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001193125-21-166678
    Item 5.07 Submission of Matters to a Vote of Security Holders
  11. 0001193125-20-147476
    Item 5.07 Submission of Matters to a Vote of Security Holders
  12. 0001193125-19-152829
    Item 5.07 Submission of Matters to a Vote of Security Holders
  13. 0001193125-18-170986
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Amgen executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/AMGN (accessed 2026).
Short form: data: Velarion

The paid brief for Amgen

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
$1,500 for the Executive Compensation Report. Both reports for $2,400.
Get the executive briefGet the board briefNo account needed.
13 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Amgen and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Amgen discloses

The companies named in AMGN's own disclosed peer group.

AbbVie Inc.Biogen Inc.Bristol-Myers Squibb CompanyEli Lilly and CompanyGilead Sciences, Inc.Johnson & JohnsonMerck & Co., Inc.Pfizer Inc.Regeneron Pharmaceuticals, Inc.Vertex Pharmaceuticals Incorporated

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy